Noncholesterol-lowering effects of statins.
Statins, 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase inhibitors, inhibit the rate-limiting enzyme in cholesterol synthesis and lead to a significant reduction of plasma lipid concentrations. As a clear correlation exists between serum cholesterol and cardiovascular risk, statins have become increasingly important in current preventive medicine. Studies prompted by the extraordinary benefits afforded by these drugs have reported minimal changes in the vasculature of hypercholesterolemic patients when compared with clinical benefits and have led to further investigations to determine the underlying reasons for these clinical benefits. The purpose of this review is to present the wide array of systems that HMG-CoA reductase inhibitors are known to influence, which range from adverse events due to coronary artery disease, stroke risk, platelet function, endothelial function, and inflammatory effects to intracellular signaling pathways that control vascular cell migration, proliferation, and differentiation.
Pierre-Paul
Daphne
D
Yale University School of Medicine, Section of Vascular Surgery, New Haven, CT, USA.
Gahtan
Vivian
V
D001778:Blood Coagulation Disorders / Q000517:prevention & control*; D003324:Coronary Artery Disease / Q000517:prevention & control*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D010024:Osteoporosis / Q000517:prevention & control; D012680:Sensitivity and Specificity; D020521:Stroke / Q000517:prevention & control; D013927:Thrombosis / Q000517:prevention & control
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors